TALPHERA, INC.

The company is a specialty pharmaceutical business dedicated to developing and commercializing therapies for medically supervised healthcare settings. Its lead pipeline product is Niyad, a regional anticoagulant formulated with nafamostat for infusion into extracorporeal circuits during continuous renal replacement therapy. The enterprise is also investigating LTX-608, a direct intravenous nafamostat formulation targeting conditions such as disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and viral infections. Intended customers and end users include hospital intensive care units, dialysis centers, and specialized clinical care providers.

Clinical development operations focus on the United States, where the business conducts registrational trials across hospital intensive care units. The company utilizes external contract manufacturing partners to produce its active drug substances and finished development formulations. Additionally, the corporate text references prior international commercial use of its core compound in Japan and South Korea, as well as European manufacturing facilities used by a third-party partner. The provided text does not state the company's specific headquarters location.

Summary of the business section of Talphera's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 12 full-time employees, most of whom work out of our corporate offices in San Mateo, CA.”